Misha Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 25-06-2024
- Paid Up Capital ₹ 0.10 M
as on 25-06-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
as on 25-06-2024
- Revenue 33.31%
(FY 2022)
- Profit 38.57%
(FY 2022)
- Ebitda 38.75%
(FY 2022)
- Net Worth 3.44%
(FY 2022)
- Total Assets 7.70%
(FY 2022)
About Misha Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Ripudaman Sharma and Monika Sharma serve as directors at the Company.
- CIN/LLPIN
U24232CH2008PTC031414
- Company No.
031414
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Oct 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Misha Biotech Private Limited offer?
Misha Biotech Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, PCD Pharma Franchise, Allopathic Cough Syrup, Ambroxol Hydrochloride Syrup, Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Antibiotic Syrup & Oral Suspension, Azithromycin Suspension Syrup, Antifungal Injection, Tablet & Syrup, Itraconazole Capsule and Tablet.
Who are the key members and board of directors at Misha Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ripudaman Sharma  | Director | 31-Oct-2008 | Current |
| Monika Sharma | Director | 31-Oct-2008 | Current |
Financial Performance of Misha Biotech.
Misha Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 33.31% increase. The company also saw a substantial improvement in profitability, with a 38.57% increase in profit. The company's net worth moved up by a moderate rise of 3.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Misha Biotech?
In 2019, Misha Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 06 Mar 2013 | ₹0.50 M | Open |
How Many Employees Work at Misha Biotech?
Unlock and access historical data on people associated with Misha Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Misha Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Misha Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
